Biotechnology Company, Retrophin Inc (NASDAQ:RTRX), shares are up in the market by 25.47% after the company announced it had signed a binding commitment on a senior secured term loan facility, valued at $40 million. The term loan provided by Athyrium Capital Management is expected to Mature in 2018 with a LIBOR plus interest rate of 10%. Retrophin Inc (NASDAQ:RTRX), weekly performance is -6.97%. On last trading day company shares ended up $13.35. Analysts mean target price for the company is $39.00. Retrophin Inc (NASDAQ:RTRX), distance from 50-day simple moving average (SMA50) is -12.55%.
On May 27, 2014, Alimera Sciences Inc (NASDAQ:ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Dan Myers, president and chief executive officer, will present at the Jefferies 2014 Healthcare Conference on Thursday, June 5, 2014 at 1:30 P.M. ET in New York, NY. Alimera Sciences Inc (NASDAQ:ALIM), fell 5.26% in last trading session and ended the day on $5.40. ALIM, return on assets is -212.70%. Alimera Sciences Inc (NASDAQ:ALIM), quarterly performance is -22.97%.
On May 15, 2014, Biostar Pharmaceuticals Inc (NASDAQ:BSPM), announced its financial results of the first quarter ended March 31, 2014. Revenue for the first quarter of 2014 increased 9.0% to approximately $13.2 million compared to $12.1 million for the first quarter of 2013. The increase is mainly attributable to the increase in sales volume of other Aoxing products and Weinan products and the addition of 4 new products at Shaanxi Weinan. The increase in sales volume is mainly due to the positive image spread by the hospital using our products. Our sales prices didn’t change much in the first quarter of 2014. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), shares moved down 0.43% in last trading session and was closed at $1.38, while trading in range of $1.38 – 1.50. Biostar Pharmaceuticals Inc (NASDAQ:BSPM),year to date (YTD) performance is -33.33%.
On May 30, 2014, Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc. (NASDAQ:ECTE), owning approximately 20% of the common stock, announced that it has filed an investor presentation detailing the case for change at Echo. Echo stockholders are strongly encouraged to view the investor presentation and Platinum’s other communications with Echo stockholders at www.morrowco.com/platinum or at the SEC website, www.sec.gov. Echo Therapeutics, Inc. (NASDAQ:ECTE), Mended the last trading day at $1.69. Company weekly volatility is calculated as 9.91% and price to cash ratio as 2.50. Duke Echo Therapeutics, Inc. (NASDAQ:ECTE), showed a positive weekly performance of 6.96%.
Leave a Reply